Eli Lilly injects $140M into U.S. insulin pen production; A third of women on asthma medications quit use during first few months of pregnancy;

@FiercePharma: Spectrum rejigs sales ops after Allos buyout, to tout its 3-drug stable. Prep for new ones, too. More | Follow @FiercePharma

> Eli Lilly ($LLY) is injection $140 million into U.S. insulin pen production at a plant in Indianapolis. Item

> Teva Pharmaceutical Industries ($TEVA) reported revenue reached $5 billion in the third quarter, up 14% from $4.3 billion in the corresponding quarter in 2011. News

> Drug-mixing pharmacy Ameridose recalled its products Wednesday, after federal health inspectors asked the company to improve its sterility testing. Report (sub. req.)

> The EMA's Pharmacovigilance Risk Assessment Committee put diclofenac-containing medicines (non-steroidal anti-inflammatory drugs) under safety review in relation to their possible cardiovascular risks. Report

> In a plan to save €2.7 billion ($3.5 billion), the region of Madrid will introduce a one-euro surcharge for medical prescriptions next year. Story

> India's government may lift a ban on pharma firm-sponsored tours for doctors. Article

> Aurobindo Pharma soared more than 8% to Rs 171 on the Bombay Stock Exchange, driven by abbreviated new drug application approvals received from the U.S. FDA. News

Medical Device News

 @FierceMedDev: Michael Mahoney, Boston Scientific's new CEO, inherits a giant in transition on day one. More | Follow @FierceMedDev

 @MarkHFierce: Advanced Cell Diagnostics pulled in $12 million in new Series B financing. More | Follow @MarkHFierce

 @DamianFierce: It's campaign season, and medical device companies are donating big. Find out how and to whom in our report. More | Follow @DamianFierce

> Medtronic closes $816M buyout of Chinese devicemaker. News

> BD completes $730M sale of labware unit. Item

> Disgraced former head of defunct French breast implant maker freed from jail. Article

Biotech News

 @FierceBiotech: Trending on FierceBiotech.com : The 2012 Biotech Graveyard. Special Report | Follow @FierceBiotech

 @JohnCFierce: Medivir would like everyone to know that JNJ's hep C drug came from them. Alios outlicensed Vertex drug, but they've always been low profile. | Follow @JohnCFierce

 @RyanMFierce: Sanofi deal bolsters Medidata in record quarter for revenue, boosts number of cloud customers in pharma. More | Follow @RyanMFierce

> Hurricane Sandy flooding wipes out years of drug research at NYU lab. Story

> Vertex partners with J&J, GlaxoSmithKline on new hep C combos. News

> FDA spurns new low-sodium drug from Cornerstone. Article

Vaccines News

 @AlisonBFierce: In search of a lasting flu vaccine: Researchers work to find decades of protection with one shot. More | Follow @AlisonBFierce

> Health officials clash over whether to scrap malaria program. Item

> Mumps vaccine succumbs to face-to-face contact. Story

> U.K.'s HPA lands $6.4M for anthrax vaccine research. Article

> Study: Flu vaccine protects against heart attacks. More

Pharma Manufacturing News

> Lonza whacking 500 jobs, 400 at Swiss API plant. Story

> Compounder recall may make drug shortages more severe. News

> Novartis adding $500M biologics plant in Singapore. Report

> Boston-area pharma plant goes up for auction to pay debts. More

And Finally... A study from the Netherlands shows almost a third of women on asthma medications stop using them during the first few months of pregnancy, despite advice that a mother's uncontrolled asthma is more dangerous to the developing fetus than the drugs. More